Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

ANI Pharmaceuticals's Return On Capital Employed Insights

ANI Pharmaceuticals (NASDAQ:ANIP) brought in sales totaling $60.93 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 442.75%, resulting in a loss of $24.14 million. In Q3, ANI Pharmaceuticals brought in $52.06 million in sales but lost $4.45 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.